It's obvious to a lot of people that these infusions are probably idiotic and possibly dangerous, so a lot of people have just dropped them. "Recent observations, which have in some ways been driven ...
Rotterdam, the Netherlands - GP IIb/IIIa inhibitors are beneficial in patients with acute coronary syndromes (ACS) not routinely scheduled for early revascularization, particularly in patients at high ...
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
An audit on the appropriateness of the use of glycoprotein (GP) IIb/IIIa inhibitors could be carried out to ensure the following: An audit on the first objective above could be carried out on all ...
RUC-4 (CeleCor Therapeutics), an investigational glycoprotein IIb/IIIa inhibitor (GPI) administered by subcutaneous injection, provides rapid and powerful platelet inhibition in patients with STEMI, ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
nearly 50 percent less bleeding at 30 days and comparable mortality at one-year when treated with Angiox(R) (bivalirudin) alone compared to unfractionated heparin or enoxaparin plus a glycoprotein IIb ...
177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A ...
Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Replacement of the September 2000 guidance with this revised guidance is not anticipated to increase costs to the NHS. Fewer patients undergoing elective percutaneous coronary intervention (PCI) will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback